XIII Annual INFOTEHNA Pharmaceutical Conference

25 - 27 May 2011, Wörthersee/Klagenfurt, Austria.
INFOTEHNA Group, leading provider of Software Solutions for Pharmaceutical Industry, is organizing its traditional (XIII) Annual Pharmaceutical Conference. Event will take place at idyllic alpine lake Woerthersee in southern Austria.

INFOTEHNA's consultants with guest speakers from Agencies and successful pharmaceutical companies will focus on areas of Regulatory Affairs, Research & Development, Quality Assurance and Quality Control.

Pre-conference day - May 25
Pre-conference day will be devided in two workshops: to newcomers INFOTEHNA's software solutions for faster, easier and efficient work with documentation will be presented, along with several case studies. To loyal customers, INFOTEHNA will unveil new functions of our system, some tricks of Submission Management and show demonstration of Training Management Tool. Event organisers will discuss Pharmacovigilance Documentation in electronic system, connection with Regulatory Authorities and much more.

Conference day - May 26
Speakers from successful Pharma companies and Regulatory Agencies will share their experiences and knowledge in 2 Streams:

1) Regulatory Affairs and Pharmacovigilance
2) Quality and Development

In Hands-on corner you will be able to work with INFOTEHNA's system and test its functionalities, consult experts and get answers to any questions concerning the use of INFOTEHNA's solutions.

For further information and registration, please visit:
http://www.infotehna.com/event/373

About INFOTEHNA
INFOTEHNA Group is with more than 20 years in the industry well established provider of hi-end Enterprise Content Management Software, delivering totally integrated solutions for mission-critical business processes in pharmaceutical industry. They are ready to validate and deploy without expensive customization, and designed with compliance regulations and best practices in mind.

INFOTEHNA Expert Series solutions have over 5000 users in more than 20 countries. With offices in Germany, USA, India, Turkey, Slovenia and Croatia, INFOTEHNA is globally present and highly experienced partner of world's largest Life Science companies.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...